Table of Contents Author Guidelines Submit a Manuscript
Journal of Diabetes Research
Volume 2016, Article ID 7292564, 8 pages
http://dx.doi.org/10.1155/2016/7292564
Review Article

Cardiac Resynchronization Therapy Outcomes in Type 2 Diabetic Patients: Role of MicroRNA Changes

Department of Medical, Surgical, Neurological, Metabolic and Aging Sciences, Second University of Naples, 80138 Naples, Italy

Received 19 March 2015; Accepted 27 March 2015

Academic Editor: Rory R. Koenen

Copyright © 2016 Celestino Sardu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. D. T. Eurich, D. L. Weir, S. R. Majumdar et al., “Comparative safety and effectiveness of metformin in patients with diabetes mellitus and heart failure: systematic review of observational studies involving 34,000 patients,” Circulation: Heart Failure, vol. 6, no. 3, pp. 395–402, 2013. View at Publisher · View at Google Scholar · View at Scopus
  2. G. Santulli, “Epidemiology of cardiovascular disease in the 21st century: updated numbers and updated facts,” Journal of Cardiovascular Disease, vol. 1, no. 1, pp. 1–2, 2013. View at Google Scholar
  3. E. S. Huang, N. Laiteerapong, J. Y. Liu, P. M. John, H. H. Moffet, and A. J. Karter, “Rates of complications and mortality in older patients with diabetes mellitus: the diabetes and aging study,” JAMA Internal Medicine, vol. 174, no. 2, pp. 251–258, 2014. View at Publisher · View at Google Scholar · View at Scopus
  4. L. R. Peterson, C. R. McKenzie, and J. E. Schaffer, “Diabetic cardiovascular disease: getting to the heart of the matter,” Journal of Cardiovascular Translational Research, vol. 5, no. 4, pp. 436–445, 2012. View at Publisher · View at Google Scholar · View at Scopus
  5. R. M. Cubbon, B. Adams, A. Rajwani et al., “Diabetes mellitus is associated with adverse prognosis in chronic heart failure of ischemic and non ischemic etiology,” Diabetes & Vascular Disease Research, vol. 10, no. 4, pp. 330–336, 2013. View at Google Scholar
  6. S. Nodari, A. Manerba, A. Vaccari et al., “Six-year prognosis of diabetic patients with coronary artery disease,” European Journal of Clinical Investigation, vol. 42, no. 4, pp. 376–383, 2012. View at Publisher · View at Google Scholar · View at Scopus
  7. A. J. Moss, W. J. Hall, D. S. Cannom et al., “Cardiac-resynchronization therapy for the prevention of heart-failure events,” The New England Journal of Medicine, vol. 361, no. 14, pp. 1329–1338, 2009. View at Publisher · View at Google Scholar · View at Scopus
  8. P. N. Peterson, M. A. Greiner, L. G. Qualls et al., “QRS duration, bundle-branch block morphology, and outcomes among older patients with heart failure receiving cardiac resynchronization therapy,” The Journal of the American Medical Association, vol. 310, no. 6, pp. 617–626, 2013. View at Publisher · View at Google Scholar · View at Scopus
  9. M. Vanderheyden, W. Mullens, L. Delrue et al., “Myocardial gene expression in heart failure patients treated with cardiac resynchronization therapy. Responders versus non responders,” Journal of the American College of Cardiology, vol. 51, no. 2, pp. 129–136, 2008. View at Publisher · View at Google Scholar · View at Scopus
  10. M. R. Gold, C. Daubert, W. T. Abraham et al., “The effect of reverse remodeling on long-term survival in mildly symptomatic patients with heart failure receiving cardiac resynchronization therapy: results of the REVERSE study,” Heart Rhythm, vol. 12, no. 3, pp. 524–530, 2015. View at Google Scholar
  11. D. T. Martin, S. McNitt, R. W. Nesto, M. K. Rutter, and A. J. Moss, “Cardiac resynchronization therapy reduces the risk of cardiac events in patients with diabetes enrolled in the multicenter automatic defibrillator implantation trial with cardiac resynchronization therapy (MADIT-CRT),” Circulation: Heart Failure, vol. 4, no. 3, pp. 332–338, 2011. View at Publisher · View at Google Scholar · View at Scopus
  12. J. G. F. Cleland, J.-C. Daubert, E. Erdmann et al., “The effect of cardiac resynchronization on morbidity and mortality in heart failure,” The New England Journal of Medicine, vol. 352, no. 15, pp. 1539–1549, 2005. View at Publisher · View at Google Scholar · View at Scopus
  13. G. B. Bleeker, M. J. Schalij, S. G. Molhoek et al., “Comparison of effectiveness of cardiac resynchronization therapy in patients <70 versus 70 years of age,” The American Journal of Cardiology, vol. 96, no. 3, pp. 420–422, 2005. View at Publisher · View at Google Scholar
  14. G. Pulignano, D. Del Sindaco, L. Tavazzi et al., “Clinical features and outcomes of elderly outpatients with heart failure followed up in hospital cardiology units: data from a large nationwide cardiology database (IN-CHF registry),” The American Heart Journal, vol. 143, no. 1, pp. 45–55, 2002. View at Publisher · View at Google Scholar · View at Scopus
  15. S. Fumagalli, S. Valsecchi, G. Boriani et al., “Comparison of the usefulness of cardiac resynchronization therapy in three age-groups (<65, 65–74 and ≥75 Years) (from the InSync/InSync ICD Italian Registry),” The American Journal of Cardiology, vol. 107, no. 10, pp. 1510–1516, 2011. View at Publisher · View at Google Scholar
  16. P. W. X. Foley, S. Chalil, K. Khadjooi, R. E. A. Smith, M. P. Frenneaux, and F. Leyva, “Long-term effects of cardiac resynchronization therapy in octogenarians: a comparative study with a younger population,” Europace, vol. 10, no. 11, pp. 1302–1307, 2008. View at Publisher · View at Google Scholar · View at Scopus
  17. R. Cutro, M. W. Rich, and P. J. Hauptman, “Device therapy in patients with heart failure and advanced age: too much too late?” International Journal of Cardiology, vol. 155, no. 1, pp. 52–55, 2012. View at Publisher · View at Google Scholar · View at Scopus
  18. D. B. Kramer, M. R. Reynolds, and S. L. Mitchell, “Resynchronization: considering device-based cardiac therapy in older adults,” Journal of the American Geriatrics Society, vol. 61, no. 4, pp. 615–621, 2013. View at Publisher · View at Google Scholar · View at Scopus
  19. C. Fantoni, F. Regoli, A. Ghanem et al., “Long-term outcome in diabetic heart failure patients treated with cardiac resynchronization therapy,” European Journal of Heart Failure, vol. 10, no. 3, pp. 298–307, 2008. View at Publisher · View at Google Scholar · View at Scopus
  20. J. George, A. Barsheshet, A. J. Moss et al., “Effectiveness of cardiac resynchronization therapy in diabetic patients with ischemic and nonischemic cardiomyopathy,” Annals of Noninvasive Electrocardiology, vol. 17, no. 1, pp. 14–21, 2012. View at Publisher · View at Google Scholar
  21. U. C. Hoppe, N. Freemantle, J. G. F. Cleland, M. Marijianowski, and E. Erdmann, “Effect of cardiac resynchronization on morbidity and mortality of diabetic patients with severe heart failure,” Diabetes Care, vol. 30, no. 3, pp. 722–724, 2007. View at Publisher · View at Google Scholar · View at Scopus
  22. M. Mangiavacchi, M. Gasparini, S. Genovese et al., “Insulin-treated type 2 diabetes is associated with a decreased survival in heart failure patients after cardiac resynchronization therapy,” Pacing and Clinical Electrophysiology, vol. 31, no. 11, pp. 1425–1432, 2008. View at Publisher · View at Google Scholar · View at Scopus
  23. A. C. Ruwald, C. Schuger, A. J. Moss et al., “Mortality reduction in relation to implantable cardioverter defibrillator programming in the Multicenter Automatic Defibrillator Implantation Trial-Reduce Inappropriate Therapy (MADIT-RIT),” Circulation: Arrhythmia and Electrophysiology, vol. 7, no. 5, pp. 785–792, 2014. View at Publisher · View at Google Scholar
  24. C. Sardu, R. Marfella, and G. Santulli, “Impact of diabetes mellitus on the clinical response to cardiac resynchronization therapy in elderly people,” Journal of Cardiovascular Translational Research, vol. 7, no. 3, pp. 362–368, 2014. View at Publisher · View at Google Scholar · View at Scopus
  25. R. Marfella, C. Di Filippo, N. Potenza et al., “Circulating microRNA changes in heart failure patients treated with cardiac resynchronization therapy: responders vs. non-responders,” European Journal of Heart Failure, vol. 15, no. 11, pp. 1277–1288, 2013. View at Publisher · View at Google Scholar
  26. C. Sardu, R. Marfella, G. Santulli, and G. Paolisso, “Functional role of miRNA in cardiac resynchronization therapy,” Pharmacogenomics, vol. 15, no. 8, pp. 1159–1168, 2014. View at Publisher · View at Google Scholar
  27. X. Luo, Z. Pan, H. Shan et al., “MicroRNA-26 governs profibrillatory inward-rectifier potassium current changes in atrial fibrillation,” The Journal of Clinical Investigation, vol. 123, no. 5, pp. 1939–1951, 2013. View at Publisher · View at Google Scholar · View at Scopus
  28. E. van Rooij, L. B. Sutherland, J. E. Thatcher et al., “Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis,” Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 35, pp. 13027–13032, 2008. View at Publisher · View at Google Scholar · View at Scopus
  29. Y. Shen, Z. Shen, L. Miao et al., “miRNA-30 family inhibition protects against cardiac ischemic injury by regulating cystathionine-γ-lyase expression,” Antioxidants & Redox Signaling, vol. 22, no. 3, pp. 224–240, 2015. View at Publisher · View at Google Scholar
  30. Z. Chen, L. Wen, M. Martin et al., “Oxidative stress activates endothelial innate immunity via sterol regulatory element binding protein 2 (SREBP2) transactivation of MicroRNA-92a,” Circulation, vol. 131, no. 9, pp. 805–814, 2015. View at Publisher · View at Google Scholar
  31. X. Liu, Y. Cheng, J. Yang et al., “Flank sequences of miR-145/143 and their aberrant expression in vascular disease: mechanism and therapeutic application,” Journal of the American Heart Association, vol. 2, no. 6, Article ID e000407, 2013. View at Publisher · View at Google Scholar
  32. G. Ruvkun and J. Giusto, “The Caenorhabditis elegans heterochronic gene lin-14 encodes a nuclear protein that forms a temporal developmental switch,” Nature, vol. 338, no. 6213, pp. 313–319, 1989. View at Publisher · View at Google Scholar · View at Scopus
  33. V. Ambros, B. Bartel, D. P. Bartel et al., “A uniform system for microRNA annotation,” RNA, vol. 9, no. 3, pp. 277–279, 2003. View at Publisher · View at Google Scholar · View at Scopus
  34. D. P. Bartel and C.-Z. Chen, “Micromanagers of gene expression: the potentially widespread influence of metazoan microRNAs,” Nature Reviews Genetics, vol. 5, no. 5, pp. 396–400, 2004. View at Google Scholar · View at Scopus
  35. V. N. Kim, “MicroRNA biogenesis: coordinated cropping and dicing,” Nature Reviews Molecular Cell Biology, vol. 6, no. 5, pp. 376–385, 2005. View at Publisher · View at Google Scholar · View at Scopus
  36. D. P. Bartel, “MicroRNAs: genomics, biogenesis, mechanism, and function,” Cell, vol. 116, no. 2, pp. 281–297, 2004. View at Publisher · View at Google Scholar · View at Scopus
  37. E. Lund, S. Güttinger, A. Calado, J. E. Dahlberg, and U. Kutay, “Nuclear export of microRNA precursors,” Science, vol. 303, no. 5654, pp. 95–98, 2004. View at Publisher · View at Google Scholar · View at Scopus
  38. A. M. Denli, B. B. J. Tops, R. H. A. Plasterk, R. F. Ketting, and G. J. Hannon, “Processing of primary microRNAs by the Microprocessor complex,” Nature, vol. 432, no. 7014, pp. 231–235, 2004. View at Publisher · View at Google Scholar · View at Scopus
  39. E. Van Rooij and E. N. Olson, “MicroRNA therapeutics for cardiovascular disease: opportunities and obstacles,” Nature Reviews Drug Discovery, vol. 11, no. 11, pp. 860–872, 2012. View at Publisher · View at Google Scholar · View at Scopus
  40. J. Y. Du, L. F. Wang, Q. Wang, and L. D. Yu, “miR-26b inhibits proliferation, migration, invasion and apoptosis induction via the downregulation of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-3 driven glycolysis in osteosarcoma cells,” Oncology Reports, vol. 33, no. 4, pp. 1890–1898, 2015. View at Publisher · View at Google Scholar
  41. B. Icli, P. Dorbala, and M. W. Feinberg, “An emerging role for the miR-26 family in cardiovascular disease,” Trends in Cardiovascular Medicine, vol. 24, no. 6, pp. 241–248, 2014. View at Publisher · View at Google Scholar
  42. X. Y. Qi, H. Huang, B. Ordog et al., “Fibroblast inward-rectifier potassium current upregulation in profibrillatory atrial remodeling,” Circulation Research, vol. 116, no. 5, pp. 836–845, 2015. View at Publisher · View at Google Scholar
  43. M. Long, X. Wan, X. La, X. Gong, and X. Cai, “miR-29c is downregulated in the ectopic endometrium and exerts its effects on endometrial cell proliferation, apoptosis and invasion by targeting c-Jun,” International Journal of Molecular Medicine, pp. 1119–1125, 2015. View at Publisher · View at Google Scholar
  44. Y. Dai, D. Dai, and J. L. Mehta, “MicroRNA-29, a mysterious regulator in myocardial fibrosis and circulating miR-29a as a biomarker,” Journal of the American College of Cardiology, vol. 64, no. 20, p. 2181, 2014. View at Google Scholar
  45. J. Wang, X. Guan, F. Guo et al., “miR-30e reciprocally regulates the differentiation of adipocytes and osteoblasts by directly targeting low-density lipoprotein receptor-related protein 6,” Cell Death & Disease, vol. 4, no. 10, article e845, 2013. View at Publisher · View at Google Scholar · View at Scopus
  46. C. W. Cheng, H. W. Wang, C. W. Chang et al., “MicroRNA-30a inhibits cell migration and invasion by down regulating vimentin expression and is a potential prognostic marker in breast cancer,” Breast Cancer Research and Treatment, vol. 134, no. 3, pp. 1081–1093, 2012. View at Google Scholar
  47. W. Pan, Y. Zhong, C. Cheng et al., “MiR-30-regulated autophagy mediates angiotensin II-induced myocardial hypertrophy,” PLoS ONE, vol. 8, no. 1, Article ID e53950, 2013. View at Publisher · View at Google Scholar · View at Scopus
  48. G. Long, F. Wang, Q. Duan et al., “Circulating miR-30a, miR-195 and let-7b associated with acute myocardial infarction,” PLoS ONE, vol. 7, no. 12, Article ID e50926, 2012. View at Publisher · View at Google Scholar · View at Scopus
  49. S. Brockway and N. J. Zeleznik-Le, “WEE1 is a validated target of the microRNA miR-17-92 cluster in leukemia,” Cancer Genetics, vol. 208, no. 5, pp. 279–287, 2015. View at Publisher · View at Google Scholar
  50. D. Chacon-Cortes, R. A. Smith, R. A. Lea, P. H. Youl, and L. R. Griffiths, “Association of microRNA 17–92 cluster host gene (MIR17HG) polymorphisms with breast cancer,” Tumor Biology, 2015. View at Publisher · View at Google Scholar
  51. C. Ye, N. X. Sun, Y. Ma et al., “MicroRNA-145 contributes to enhancing radiosensitivity of cervical cancer cells,” FEBS Letters, vol. 589, no. 6, pp. 702–709, 2015. View at Publisher · View at Google Scholar
  52. H. Liang, Z. Jiang, G. Xie, and Y. Lu, “Serum microRNA-145 as a novel biomarker in human ovarian cancer,” Tumor Biology, 2015. View at Publisher · View at Google Scholar
  53. T. Han, X. P. Yi, B. Liu, M. J. Ke, and Y. X. Li, “MicroRNA-145 suppresses cell proliferation, invasion and migration in pancreatic cancer cells by targeting NEDD9,” Molecular Medicine Reports, vol. 11, no. 6, pp. 4115–4120, 2015. View at Publisher · View at Google Scholar
  54. B. Hu, J. T. Song, H. Y. Qu et al., “Mechanical stretch suppresses microRNA-145 expression by activating extracellular signal-regulated kinase 1/2 and upregulating angiotensin-converting enzyme to alter vascular smooth muscle cell phenotype,” PLoS ONE, vol. 9, no. 5, Article ID e96338, 2014. View at Publisher · View at Google Scholar · View at Scopus
  55. M. Ohnaka, A. Marui, K. Yamahara et al., “Effect of microRNA-145 to prevent vein graft disease in rabbits by regulation of smooth muscle cell phenotype,” The Journal of Thoracic and Cardiovascular Surgery, vol. 148, no. 2, pp. 676–682.e2, 2014. View at Publisher · View at Google Scholar · View at Scopus
  56. E. van Rooij and S. Kauppinen, “Development of microRNA therapeutics is coming of age,” EMBO Molecular Medicine, vol. 6, no. 7, pp. 851–864, 2014. View at Publisher · View at Google Scholar
  57. H. L. A. Janssen, H. W. Reesink, E. J. Lawitz et al., “Treatment of HCV infection by targeting microRNA,” The New England Journal of Medicine, vol. 368, no. 18, pp. 1685–1694, 2013. View at Publisher · View at Google Scholar · View at Scopus
  58. G. Santulli, A. Wronska, K. Uryu et al., “A selective microRNA-based strategy inhibits restenosis while preserving endothelial function,” The Journal of Clinical Investigation, vol. 124, no. 9, pp. 4102–4114, 2014. View at Publisher · View at Google Scholar